What is the recommended infusion protocol for donanemab (Kisunla) in Alzheimer's disease, including dose, infusion rate, premedication, MRI monitoring schedule, and management of ARIA?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Donanemab (Kisunla) Infusion Protocol

Administer donanemab as a 30-minute IV infusion every 4 weeks using a graduated dosing schedule: 350 mg (infusion 1), 700 mg (infusion 2), 1,050 mg (infusion 3), and 1,400 mg (infusion 4 and beyond), with mandatory MRI surveillance prior to infusions 2,3,4, and 7 to monitor for ARIA. 1

Dosing Schedule

The FDA-approved protocol uses a titrated approach:

  • Infusion 1: 350 mg
  • Infusion 2: 700 mg
  • Infusion 3: 1,050 mg
  • Infusion 4 and beyond: 1,400 mg

Each infusion is administered over approximately 30 minutes every 4 weeks 1. Recent evidence suggests this graduated titration significantly reduces ARIA-E risk (13.7% vs 23.7% with standard dosing) while maintaining comparable amyloid reduction 2.

If an infusion is missed, resume at the same dose as soon as possible, maintaining the 4-week interval 1.

Preparation and Administration

Dilution requirements:

  • Dilute with 0.9% sodium chloride injection only
  • Final concentration: 4-10 mg/mL
  • Allow vials to reach room temperature before preparation
  • Inspect for particulate matter (solution should be clear to opalescent, colorless to slightly yellow/brown) 1

Infusion specifics:

  • Administer over 30 minutes via IV infusion
  • Use aseptic technique throughout preparation 1

MRI Monitoring Schedule

Baseline MRI: Obtain within 12 months prior to treatment initiation 1, 3

Surveillance MRIs required:

  • Prior to infusion 2 (week 4)
  • Prior to infusion 3 (week 8)
  • Prior to infusion 4 (week 12)
  • Prior to infusion 7 (week 24) 1, 3

Additional monitoring: Consider MRI prior to the 12th dose in higher-risk individuals (APOE ε4 homozygotes, baseline microhemorrhages) 3. Obtain off-protocol MRI immediately if symptoms suggestive of ARIA develop (headache, confusion, visual disturbances, gait difficulties) 1.

ARIA Management

ARIA-E (Edema/Effusions)

Asymptomatic mild ARIA-E: May continue dosing at current schedule 1

Asymptomatic moderate or severe ARIA-E: Suspend dosing until radiographic resolution on MRI and consider follow-up MRI in 2-4 months 1

Symptomatic mild ARIA-E: May continue based on clinical judgment 1

Symptomatic moderate or severe ARIA-E: Suspend dosing until resolution 1

ARIA-H (Microhemorrhages/Hemosiderin)

Asymptomatic mild ARIA-H: Continue dosing 1

Asymptomatic moderate or severe ARIA-H: Suspend dosing until radiographic stabilization 1

Any symptomatic ARIA-H: Suspend dosing until stabilization and symptom resolution 1

Intracerebral hemorrhage >1 cm: Suspend dosing; use clinical judgment regarding continuation vs permanent discontinuation after stabilization 1

Most ARIA-E occurs by the third infusion (approximately month 3) in 58.3% of affected patients 4. Symptoms typically include headache and confusional state 4.

Pre-Treatment Requirements

Mandatory assessments:

  • Confirm amyloid-β pathology by PET or CSF 1, 3
  • APOE ε4 genotyping (to stratify ARIA risk) 1, 3
  • Baseline MRI within 12 months 1, 3

Exclusion criteria:

  • 4 cerebral microbleeds on baseline MRI

  • Cortical superficial siderosis
  • Major vascular contribution to cognitive impairment 3

Patient eligibility:

  • Mild cognitive impairment or mild dementia (Clinical Stages 3-4)
  • MMSE 20-30
  • Biomarker-confirmed AD pathology 1, 3

APOE ε4 Risk Stratification

APOE ε4 status is the strongest predictor of ARIA-E risk:

  • ε4/ε4 homozygotes: 33% ARIA-E risk
  • ε4 heterozygotes: 7.1% ARIA-E risk
  • Non-carriers: 4.3% ARIA-E risk 5, 4

Testing should be performed before treatment initiation, with thorough discussion of implications. Treatment can proceed without genotyping, but ARIA risk cannot be stratified 1.

Treatment Discontinuation

Consider stopping donanemab when:

  • Amyloid plaques reduced to minimal levels on PET imaging
  • Typically assessed at 12-18 months after treatment initiation 1, 3

In clinical trials, dosing was stopped based on predefined amyloid reduction thresholds on PET 1, 6.

Critical Safety Considerations

Common pitfalls:

  • Failing to obtain pre-treatment MRI or APOE genotyping
  • Missing scheduled surveillance MRIs (particularly before infusions 2-4 when ARIA-E risk peaks)
  • Not recognizing subtle ARIA symptoms (transient confusion, mild headache)
  • Continuing treatment with moderate/severe ARIA-E

The graduated dosing schedule is essential—starting at full dose increases ARIA-E risk substantially 2. Most ARIA-E cases in early trials occurred in higher dose groups 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.